



12 December 2023

Shareholder Update

1

Myopharm[®] completes purchase of TriGlytza[™]

- After a 3-year collaboration with Arkay Therapeutics LLC & extensive due diligence Myopharm completes the purchase of TriGlytza[™] (RK-01) Intellectual Property rights.
- TriGlytza[™] (RK-01) is potentially a mega blockbuster (Metformin[®]) (Ozempic[®]) adjunct or monotherapy for preserving beta cell function decline, which could extend the life of these treatments.
- Quarterly royalties received from licensing OMNI-D[®]
- December 2023 Options Expiry

Myopharm Limited is pleased to announce the acquisition of TriGlytza[™] (RK-01) a combination beta-cell-centric inflammatory pathway technology, originally developed by Arkay Therapeutics LLC. While TriGlytza[™] is a novel first in class beta cell centric drug in development as an adjunctive therapy to treat the high number of patients (over 50%) failing current antidiabetic therapies, as it is a repurposed combination product, it also presents as a potential lower development cost, risk and time to market solution to address this huge unmet need in diabetes care.

The purchase includes the United States Patent US 9,839,644 B2 and the FDA approved Investigational New Drug (IND) 136121 covering all 68 metabolic claims (including NASH and other Insulin Resistant Diseases) and all intellectual property. By mutual agreement the purchase price remains undisclosed. The agreement also provides Myopharm with continued access to Arkay Therapeutics LLC team of globally renowned endocrine and diabetes experts.

Myopharm to undertake development of a Type 1 and 2 Diabetes combination drug, with the prescription drug market predicted to be worth \$96b by 2029. TriGlytza[™] is anticipated to

benefit patients as a standalone or adjunct therapy or for the large medication intolerant group intolerant to treatments such as GLP-1 Agonists (Ozempic®) and SGLT2 inhibitors (Metformin®), which are used to control blood sugar levels and weight, which is crucial for managing diabetes and preventing complications.

OMNI-D®

Myopharm has received a first full quarter licensing royalties from BIO-E Australia.

Ongoing discussions are currently underway in Japan, South Africa and USA for further potential multinational licensing.

Myopharm CEO and Executive Chair Karinza Phoenix said *“with the recent Australian Government inquiry into Diabetes and a global focus on Beta Cell dysfunction technologies, acquisition of TriGlytza™ places Myopharm at the forefront of diabetes therapies innovation.”*

December 2023 Options Expiry

Myopharm currently has on issue 2.22 million options exercisable at \$0.16 expiring 14 December 2023, which if exercised would raise \$0.35 million. The options are not underwritten and shareholders holding these options have been advised of their imminent expiry.

The Company would like to take this opportunity to offer any shortfall to other shareholders who would like to increase their holding in the Company. Please contact us at investor@myopharm.com should you wish to discuss the opportunity to participate.

Karinza Phoenix

Myopharm Limited

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Release authorised by the Executive Chair and Chief Executive Officer of Myopharm Limited

For Investor Enquiries, please get in touch with us at Investor@myopharm.com.

About Myopharm

Website: www.myopharm.com

Myopharm is a diabetes focused company developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our aim is to reduce metabolic diseases that millions of people worldwide are at risk of.

International Diabetes Federation released an alarming growth rate in the prevalence of diabetes, with over 800 million adults worldwide living with diabetes. Closer to home, diabetes is now the fastest-growing chronic condition globally.